Send to

Choose Destination
See comment in PubMed Commons below
J Dermatolog Treat. 2015 Jun;26(3):284-90. doi: 10.3109/09546634.2014.933766. Epub 2014 Jul 18.

The effect of 4% sodium cromoglicate cutaneous emulsion compared to vehicle in atopic dermatitis in children--A meta-analysis of total SCORAD scores.

Author information

EmStat Ltd. , Leicester , UK and.


An emulsion containing 4% sodium cromoglicate (4% SCG emulsion) has been developed for the treatment of atopic dermatitis in children. We have conducted a meta-analysis of the primary outcome measure (the change in SCORAD score) used in randomized clinical trials (RCTs) with this product. We conducted a search of standard using the keywords, sodium cromoglicate, cromolyn sodium, topical, atopic dermatitis, clinical trial. We identified 19 clinical studies of which 3 used this 4% SCG emulsion formulation, one was a RCT using the change in SCORAD score. We were given access to two further unpublished RCTs, with this measure. The RCTs included 490 subjects (mean age 5.3 years). Each RCT was multicentre of 12 weeks duration, comparing 4% SCG emulsion with the vehicle in which the SCG was dissolved. Using study as the unit and the fixed effect model, the mean difference (95% CI) in the change in SCORAD score was -2.82 (-5.36; -0.29), pā€‰=ā€‰0.03. Using centre as the unit, and the fixed effect model, the mean difference (95% CI) in the change in SCORAD score was -2.82 (-5.82; -0.46), pā€‰=ā€‰0.02. These results support the efficacy of this new topical treatment in children with atopic dermatitis.


Children; SCORAD; cromoglicate; eczema; meta-analysis; topical

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center